Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Figitumumab + Docetaxel in Advanced Breast Cancer
NCT00678626Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Apr 2009
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of figitumumab in breast cancer, sponsored by Pfizer. Planned start Apr 2009; status: withdrawn.
02
Drugs
figitumumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00678626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678626.